I

n a setback for the pharmaceutical industry, the Nevada state assembly on Thursday voted in favor of a controversial bill aimed at lowering prices for diabetes medicines. The legislation, which passed the state senate last week, now goes to Governor Brian Sandoval.

The bill is designed to lower costs by requiring drug makers to report pricing histories, disclose costs, and notify state officials and insurers in advance of price hikes above inflation. And a recently added amendment would also require drug companies to disclose rebates paid to pharmacy benefit managers, the middlemen that negotiate favorable insurance coverage.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi Ed I am out of pocket until after Memorial Day. I would Contact Genia Long at Analysis Group about CRADAs . She is more up to date than me Henry

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy